SCHEMBL7529439

SCHEMBL7529439

Cc1ccc(-c2cc(OC(C)C)ccc2C(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
KMT2A Q03164 2/20 0.47
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MCL1 Q07820 3/20 0.45
ACACB O00763 2/20 0.44
ACACA Q13085 2/20 0.44
DHODH Q02127 1/20 0.44
XDH P47989 1/20 0.43
FFAR4 Q5NUL3 2/20 0.43
PRKAB2 O43741 1/20 0.43
PRKAG1 P54619 1/20 0.43
PRKAA2 P54646 1/20 0.43
PRKAA1 Q13131 1/20 0.43
PRKAG3 Q9UGI9 1/20 0.43
PRKAG2 Q9UGJ0 1/20 0.43
PRKAB1 Q9Y478 1/20 0.43
MAPT P10636 1/20 0.43
NLRP1 Q9C000 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8984342 0.92 ALDH1A1 (0.67) ALDH1A1KMT2ARXRARXRBSMN1; SMN2
SCHEMBL6492074 0.88 ALDH1A1 (0.61) ALDH1A1KMT2ARXRARXRBSMN1; SMN2
SCHEMBL592412 0.87 ALDH1A1 (0.59) ALDH1A1KMT2ARXRARXRBSMN1; SMN2
SCHEMBL9514380 0.85 PTGER4 (0.45) ALDH1A1KMT2ASMN1; SMN2MCL1XDH
SCHEMBL8566031 0.84 SMN1; SMN2 (0.64) ALDH1A1KMT2ASMN1; SMN2MCL1XDH
SCHEMBL7525069 0.82 ALDH1A1 (0.43) ALDH1A1KMT2AACACBACACAFFAR4
SCHEMBL6498971 0.80 HDAC7 (0.57) ALDH1A1KMT2ASMN1; SMN2MCL1PRKAB2
SCHEMBL5696709 0.78 SMN1; SMN2 (0.64) ALDH1A1SMN1; SMN2PRKAB2PRKAG1PRKAA2
SCHEMBL2597797 0.78 ALDH1A1 (0.57) ALDH1A1KMT2ARXRARXRBSMN1; SMN2
SCHEMBL9682972 0.78 KMT2A (0.44) ALDH1A1KMT2ASMN1; SMN2MCL1XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486141-B2 TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. MERCK FROSST CANADA & CO. (CA) 2002-11-26 US disclosed
EP-1244677-A1 PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA INC. (CA) 2002-10-02 EP disclosed
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) MERCK FROSST CANADA LTD. (CA) 2002-05-02 US disclosed
WO-2001046203-A1 PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA & CO. (CA) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) PTPRO, PPM1B, PTPA ALDH1A1 600/4885KMT2A 3404/4885RXRA 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.